On a day like today, it's worth remembering how wrong markets can be:
In February this year, MYX reported these key figures to the market:
- Underlying EBITDA +$8.0M (for 6mths), Underlying Cashflow from continuous operations -$19.2M (for 6 months), Nextstellis cycles for the last months (Dec) 40K, share price rose to $7.4
First 4 months of FY25, just 2 weeks ago, MYX reports these equivalent figures to the market:
- Underlying EBITDA +$14.7M (for 4mths), Underlying Cashflow from continuous operations +$16.1M (for 4 months), Nextstellis cycles for the last month (Oct) 51.5K, share price drops to $4 and recovers to $5.2.
I think this is a great buying opportunity. I know that I have selectively left out the somewhat mediocre dermatology result but EBITDA, Cashflow and Nextstellis cycles are the main drivers right now.
(20min delay)